Skip to main content
NCBI home page
Archives of Medical Science : AMS logoLink to Archives of Medical Science : AMS
. 2026 Jan 20;22(3):1381–1388. doi: 10.5114/aoms/216044

Serum total bile acids are associated with coronary artery calcification as assessed by non-gated chest computed tomography: a multicenter study

Yuxuan Tong 1, Xiao Chen 2,*, Dongdong Wang 1, Xuefei Zhang 1, Yuxin Pan 1, Mengjia Chen 3, Hangyi Zhou 4, Jianhua Wang 2, Dongling Lv 1,*
PMCID: PMC13426178  PMID: 42540657

Abstract

Introduction

Coronary artery calcification (CAC) is a risk factor for cardiovascular disease (CVD). The association between serum total bile acid (TBA) concentration and CAC has not been investigated, even though bile acid may act as a mediator between gut microbiota and CVD. We examined this relationship in a general Chinese population.

Material and methods

This cross-sectional study included 2133 people who underwent computed tomography (CT) scans for lung cancer screening between 2018 and 2020. Information on medical history, laboratory test results, and demographics was collected from medical records. CAC was assessed on non-gated chest CT images. Multivariable logistic regression analysis and restricted triple spline analysis were applied to examine the correlation between TBA and CAC risk.

Results

CACs were detected in 426 of 2133 participants. Participants with higher TBA concentrations had a considerably higher prevalence of CAC (33.4% in the fourth quartile and 11.5% in the first quartile, p < 0.001). TBA was closely associated with CAC, as determined by multivariable logistic regression analysis (OR = 1.05, 95% CI: 1.00–1.10). The fourth TBA quartile was significantly associated with a high incidence of CAC in the general population (OR = 1.76, 95% CI: 1.02–3.06), in older adults (OR = 1.66, 95% CI: 1.03–2.68), and in subjects without diabetes (OR = 1.62, 95% CI: 1.07–2.45) or hypertension (OR = 1.74, 95% CI: 1.16–2.63) when compared to the first TBA quartile.

Conclusions

A substantial and positive correlation was found between elevated TBA and CAC. The causal relationship between TBA and CAC risk should be investigated in longitudinal studies.

Keywords: total bile acids, coronary artery calcification, non-gated chest computed tomography

Introduction

Bile acids are produced by hepatocytes and facilitate lipid absorption in the intestinal lumen. They are associated with vascular diseases through various mechanisms, including direct involvement in lipid metabolism, modulation of inflammatory responses, and regulation of immune cell expression [1–4]. Research has indicated that both cerebrovascular disease and coronary artery plaque are associated with reduced fecal bile acid excretion (BAE) [1, 5–9]. The potential connection between gut microbiota and cardiovascular health has also drawn attention to the role of bile acids [2, 6, 10, 11]. Since serum total bile acid (TBA) levels are strongly correlated with various metabolic diseases and cardiovascular risk [5–9], TBA serves as a practical and efficient biomarker for screening and monitoring cardiovascular disease (CVD) and metabolic health across diverse populations.

CVD is escalating into a major global health issue, accounting for nearly one-third of annual deaths worldwide [12–17]. Coronary artery calcification (CAC), an early lesion of coronary atherosclerosis that progresses with the disease, is recognized as a robust marker of adverse cardiovascular events and exhibits the highest predictive value among assessed risk factors [18, 19]. CVD risk is typically quantified using the CAC score [20, 21]. Multi-detector computed tomography (CT) is commonly employed for coronary artery disease diagnosis [22–25]. Although BAE and gut microbiota-related bile acids are established as independent CVD risk factors [5, 26, 27], their integration into traditional risk assessment frameworks remains limited. Several studies have investigated the association between serum bile acid level and coronary artery disease (CAD) in subjects with suspected CAD [28] or the association between serum bile acid and high-risk coronary artery plaques in asymptomatic population [29]. However, the relationship between serum TBA levels and CAC risk has not received much research attention. A growing body of evidence indicates that the bile acid network is intricately linked to the pathogenesis of vascular calcification [30].

We hypothesized that the serum TBA level might also be associated with CVD risk. The correlation between CAC and TBA among the general Chinese population was examined in this study.

Material and methods

Participants

Participants who underwent CT lung cancer screening between 2016 and 2020 were initially considered. Our medical record system identified 11,606 individuals. Inclusion criteria were: age ≥ 18 years and high-quality cardiac CT scans suitable for CAC assessment. Exclusion criteria comprised: history of cancer, autoimmune disease, prior cardiac surgery or coronary stenting, severe renal or hepatic insufficiency, incomplete medical records, or severe cardiac motion artifacts. Ultimately, 2,133 participants who had undergone serum bile acid testing were enrolled (Figure 1). The Institutional Academic Committee approved this retrospective cross-sectional study (approval No. 2019-NL-158). Informed consent was waived by the Institutional Ethics Committee owing to the retrospective design. The study was conducted in full accordance with the Declaration of Helsinki.

Figure 1.

Figure 1

Open in a new tab

Flowchart of participant selection

Data collection

Data on characteristics – including age, sex, and body mass index (BMI) – were collected, along with laboratory test results such as TBA, blood glucose, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides (TG), creatinine, aspartate transaminase (AST), serum albumin, and uric acid. Medical history information, including diagnoses of diabetes mellitus, cancer, chronic renal disease (defined as an estimated glomerular filtration rate [eGFR] < 60 ml/min/1.73 m2), and blood pressure, was also obtained. Blood samples were collected from participants in the morning after a minimum 8-hour overnight fast. TBA (µmol/l) was measured using an automated biochemical analyzer with the enzymatic cycling method. This information has been included in the revised manuscript. All laboratory tests were performed on the same day as the chest CT scan.

Definition of coronary artery calcification

Numerous studies have demonstrated the feasibility of determining CAC using non-electrocardiogram (ECG)-gated chest CT [22, 23]. In this study, CAC was evaluated using nonenhanced, non-ECG-gated CT, as described in our earlier publication [31]. Briefly, CT examinations were performed using three scanners: OptimaCT660, GE, USA; Brilliance 64, Philips, Netherlands; SOMATOM go.Top, Siemens, Germany. The scanning parameters included a slice thickness of 0.625–1.25 mm, a tube voltage of 120 kV, automatic tube current modulation, and no ECG gating. Two radiologists (XC and MC), each with 5–10 years of experience in cardiac radiology, independently assessed the presence of CAC. Both radiologists were blinded to the clinical data. In cases of disagreement, a senior cardiac radiologist (JW) was consulted to reach a consensus. An example of CAC detected on non-gated chest CT is provided in Supplementary Figure S1. CAC was defined as the presence of calcification with a density greater than 130 Hounsfield units in any coronary artery. Agatston scoring was not performed due to the presence of calcification and motion artifacts in non-ECG-gated chest CT images.

Statistical analysis

For analysis of statistics, IBM SPSS (version 29.0) and R (version 4.4.1) were implemented. Participants with missing data accounted for less than 5% of the total sample. Missing values were handled using mean imputation for continuous variables. Quantitative data that were not normally distributed are presented as the median (interquartile range), while normally distributed data are presented as the mean ± standard deviation. For categorical variables, data are expressed as numbers (percentages). The Mann-Whitney U test was performed to determine whether the nonnormally distributed data differed significantly between groups. To compare categorical variables, the χ2 test was applied. The inter-rater reliability for CAC evaluation was analyzed using the kappa test. To ascertain the relationship between TBA and the risk of CAC, multivariable logistic regression analysis was employed. The quartiles of TBA were Q1 < 1.90, Q2 1.90–2.80, Q3 2.80–4.30, and Q4 > 4.30. Demographic information, factors related to CAC and TBA were considered as confounders. Age, sex, and body mass index were taken into account in Model 1; liver and renal function, diabetes mellitus, uric acid, albumin, blood pressure, and hepatic CT attenuation were further taken into account in Model 2; and LDL-c, TC, and HDL-c were further taken into account in Model 3. Male and female individuals over 50 with or without diabetes or hypertension were subjected to subgroup analysis. The dose-response relationship regarding the TBA index and the risk of CAC was evaluated by limited triple splines after variables were taken into consideration. Differences with a p value less than 0.05 were considered statistically significant.

Results

Participant characteristics

The mean age of the participants was 48.7 ±14.2 years, and 56.1% were male. Among the 2133 participants, 426 had CAC. Inter-rater reliability for CAC assessment was high (k = 0.99). Participants were categorized into quartiles based on their TBA levels. Baseline characteristics are summarized in Table I. Higher TBA levels were associated with lower albumin and HDL-C levels (p < 0.05), and with higher AST, creatinine, and uric acid levels (p < 0.01). Additionally, compared with the first TBA quartile, the fourth quartile showed a higher prevalence of CAC and diabetes mellitus (p < 0.01). Figure 2 illustrates the prevalence of CAC in the overall population and sex-specific subgroups. In the overall population, CAC prevalence increased with age, rising notably between the ages of 40 and 50, and was particularly high in the 60–80-year age group. Between ages 40 and 80, males had a higher prevalence of CAC than females.

Table I.

Characteristics of subjects across total bile acid quartiles

Parameter Total bile acid
Q1 (n = 550) Q2 (n = 526) Q3 (n = 551) Q4 (n = 506) P-value
Age [years] 44.5 ±12.45 46.67 ±13.67 49.9 ±14.72 53.4 ±15.99 < 0.001
Sex (male) 285 (51.8%) 261 (49.6%) 319 (57.9%) 329 (65.0%) <0.001
BMI [kg/m2] 25.43 ±4.30 24.96 ±4.26 25.16 ±2.16 25.40 ±3.90 < 0.001
Liver CT attenuation (HU) 55.71 ±8.56 55.03 ±9.38 55.01 ±9.52 55.20 ±9.18 0.56
AST [U/l] 21.94 ±6.70 22.49 ±8.20 23.40 ±9.59 24.48 ±11.96 < 0.001
Albumin [g/l] 41.72 ±2.94 41.49 ±3.18 41.13 ±3.04 41.08 ±3.30 0.006
Uric acid [µmol/l] 296.7 ±92.3 304.6 ±101.2 307.8 ±93.5 319.5 ±89.6 0.001
Creatinine [µmol/l] 71.83 ±14.41 72.05±15.34 73.47 ±15.42 75.37 ±15.72 < 0.001
Total bile acid [µmol/l] 1.31 ±0.45 2.41±0.25 3.50 ±0.43 7.16 ±2.34 < 0.001
HDL-C [mmol/l] 1.97 ±0.25 1.58 ±0.11 1.37 ±0.09 1.12 ±0.13 0.034
LDL-C [mmol/l] 3.11 ±0.79 2.89 ±0.79 2.95 ±0.79 2.88 ±0.82 < 0.001
TC [mmol/l] 4.86 ±0.89 4.75 ±0.94 4.83 ±0.98 4.68 ±0.99 0.009
TG [mmol/l] 1.47 ±1.57 1.45 ±1.22 1.56 ±1.30 1.61 ±1.47 0.22
SBP [mm Hg] 127.1 ±16.3 126.9 ±16.07 128.3 ±16.32 129.8 ±14.6 0.14
DBP [mm Hg] 75.5 ±13.18 75.46 ±13.0 76.06 ±10.65 76.61 ±13.27 0.13
Diabetes 14 (2.5%) 20 (3.8%) 29 (5.2%) 38 (7.5%) 0.001
CKD 4 (0.7%) 1 (0.2%) 4 (0.7%) 3 (0.6%) 0.61
Coronary artery calcification 63 (11.5%) 82 (15.6%) 112 (20.3%) 169 (33.4%) < 0.001
Open in a new tab

AST – aspartate aminotransferase, BMI – body mass index, CKD – chronic kidney disease, CT – computed tomography, DBP – diastolic blood pressure, HDL-C – high-density lipoprotein cholesterol, HU – Hounsfield unit, LDL-C – low-density lipoprotein cholesterol, SBP – systolic blood pressure, TC – total cholesterol, TG – triglyceride.

Figure 2.

Figure 2

Open in a new tab

Prevalence of coronary artery calcification (CAC) in the overall, male, and female populations in different age groups (20–30, 30–40, 40–50, 50–60, 60–70,70–80 and > 80 years). Prevalence of CAC increased with advancing age in the overall, male, and female populations

Association between TBA and CAC

To examine the association between TBA and coronary artery calcium (CAC), we performed multivariable logistic regression analyses (Table II). After adjusting for age, sex, BMI, liver function, renal function, diabetes mellitus, albumin, uric acid, blood pressure, liver CT attenuation, and serum lipid levels, TBA remained independently associated with CAC when analyzed as a continuous variable (odds ratio [OR] = 1.05, 95% confidence interval [CI]: 1.00–1.10). A positive dose-response relationship between TBA and CAC risk was observed using restricted cubic spline curves (Figure 3).

Table II.

Association between total bile acid and risk of coronary artery calcification

Variable Model 1 P-value Model 2 P-value Model 3 P-value
OR (95% CI) OR (95% CI) OR (95% CI)
Overall Bile acid (continuous) 1.05 (1.01–1.10) 0.04 1.05 (1.01–1.10) 0.039 1.05 (1.00–1.10) 0.045
Q1 (< 1.9) 1 1 1
Q2 (1.9–2.8) 1.19 (0.78–1.81) 0.42 1.13 (0.74–1.73) 0.56 1.10 (0.71–1.70) 0.66
Q3 (2.8–4.3) 1.14 (0.76–1.70) 0.54 1.10 (0.73–1.67) 0.64 1.09 (0.71–1.69) 0.69
Q4 (> 4.3) 1.81 (1.22–2.68) 0.003 1.74 (1.17–2.59) 0.006 1.76 (1.02–3.06) 0.044
Older than 50 years Bile acid (continuous) 1.03 (0.98–1.09) 0.22 1.03 (1.98–1.09) 0.22 1.04 (0.98–1.09) 0.22
Q1 (< 1.9) 1 1 1
Q2 (1.9–2.8) 1.14 (0.69–1.88) 0.62 1.10 (0.66–1.83) 0.72 1.07 (0.64–1.78) 0.81
Q3 (2.8–4.3) 1.16 (0.72–1.86) 0.55 1.13 (0.69–1.83) 0.63 1.10 (0.68–1.79) 0.69
Q4 (> 4.3) 1.76 (1.11–2.81) 0.017 1.72 (1.07–2.76) 0.026 1.66 (1.03–2.68) 0.037
Open in a new tab

Model 1 was adjusted for age, sex, and body mass index; Model 2 was further adjusted for liver function, renal function, diabetes, albumin, uric acid, blood pressure, and liver CT attenuation. Model 3 was further adjusted for low-density lipoprotein cholesterol, total cholesterol, and high-density lipoprotein cholesterol. CI – confidence interval, HDL – high-density lipoprotein cholesterol, OR – odds ratio.

Figure 3.

Figure 3

Open in a new tab

Restricted cubic splines show the multivariable- adjusted odds ratio for risk of coronary artery calcification according to total bile acid (TBA). Age, sex, and body mass index, liver function, renal function, diabetes, uric acid, blood pressure, liver CT attenuation, low-density lipoprotein cholesterol, total cholesterol, albumin, and high-density lipoprotein cholesterol were adjusted. A dose-response relationship was observed between serum TBA and CAC risk

CI – confidence interval, OR – odds ratio.

We further evaluated the relationship between categorical TBA levels and CAC. After full adjustment for the same covariates, the highest TBA quartile was significantly associated with a higher prevalence of CAC (OR = 1.76, 95% CI: 1.02–3.06) compared with the lowest quartile.

Subgroup analyses were then conducted on participants who were above 50 years of age (Table II), male or female (Supplementary Table SI), and had or did not have hypertension or diabetes. The fully adjusted model (controlling for age, sex, BMI, diabetes mellitus, hepatic and renal function, blood pressure, serum uric acid, albumin levels, and lipid levels) showed that the fourth TBA quartile was significantly predictive of CAC in subjects aged ≥ 50 years (OR = 1.66, 95% CI: 1.03–2.68), without hypertension (OR = 1.74, 95% CI: 1.16–2.63), without diabetes (OR = 1.62, 95% CI: 1.07–2.45), and those who were male (OR = 1.92, 1.18–3.14).

Discussion

Many studies have shown that bile acids are associated with cardiovascular disease [6, 32]. Several have also demonstrated an association between TBA and coronary artery diseases [28, 29]. However, to our knowledge, the relationship between CAC and total serum bile acid levels in the general population is rarely reported. It seems that only Zhang et al. have demonstrated an association between serum bile acid and high-risk coronary artery plaques in an asymptomatic population [29]. According to our data, TBA is associated with CAC. Compared to participants with low TBA levels, those with high TBA levels were at higher risk of developing CAC.

An association between reduced BAE and vascular diseases has been reported [5]. Charach et al. found that patients with coronary artery disease had significantly lower BAE levels than controls, and those with high BAE levels (> 415 mg/day) exhibited lower cardiovascular mortality than those with low BAE levels [33]. A recent study also suggested that high BAE levels may have a therapeutic effect against peripheral vascular disease [5]. The relationship between bile acids and coronary artery calcium (CAC) has been examined in several studies [34, 35]. Jovanovich et al. reported that circulating deoxycholic acid (DCA), a secondary bile acid, was associated with CAC volume score [34], but not with the prevalence, incidence, or progression of CAC in patients with chronic kidney disease (CKD) [35]. Our data also indicated that TBA was not associated with CAC in subjects with hypertension or diabetes. While many studies have found no significant association between serum bile acid levels and coronary artery disease [28, 36], limited research has specifically investigated the relationship between serum bile acid levels and CAC. However, little research has been conducted on the connection between serum bile acid and CAC. Zhang et al. determined that the degree of coronary artery stenosis and high-risk coronary arterial plaques was correlated with a high serum TBA level in an asymptomatic population [29]. These results were confirmed by our investigation, which also showed an association between TBA and CAC.

Bile acids may influence cardiovascular health through multiple mechanisms, primarily involving cardiovascular signaling pathways and modulation of gut microbiota [10, 37, 38]. Bile acid receptors include G protein-coupled receptors (GPCRs) and nuclear receptors [39], which are implicated in cardiomyocyte apoptosis, cardiac injury, and vascular metabolism [40–44]. The role of gut microbiota (GM) in cardiovascular disease has gained increasing attention [11, 45–47]. As metabolites of GM [48, 49], bile acids can act on various ion channels and receptors in the myocardium and vasculature to modulate cardiac function. For instance, ursodeoxycholic acid, the most hydrophilic bile acid, has been shown to prevent refractory arrhythmias [50]. Additionally, bile acids help maintain intestinal barrier function and support cardiovascular health through several pathways: they disrupt bacterial integrity, directly modulate GM composition, inhibit bacterial overgrowth, and prevent bacterial translocation and endotoxemia via FXR-mediated activation of gut-protective genes.

Our research has several advantages. We may be the first to investigate the association between serum TBA and CAC in the general population. Secondly, we have a sizable sample size. There are also some limitations to our study. First, we only reported the existence or absence of CAC without evaluating its severity because calcification artifacts during non-ECG-gated chest CT may have affected the accurate evaluation of Agatston scoring. Future studies are needed to evaluate the association between TBA and Agatston score. Second, the analysis did not account for certain confounding factors, such as dietary habits, drinking and smoking habits, medications, and physical activity. Diabetes and hypertension are the two main chronic diseases which may be related to drinking and smoking habits and medications use. In our subgroup analyses, we found that TBA was also associated with CAC in subjects without diabetes and hypertension, possibly suggesting that TBA may be associated with CAC independently of those factors. Third, the sample size in subjects with hypertension and diabetes may be insufficient, increasing the likelihood of a type I error. The association between TBA and CAC in subjects without hypertension and diabetes should be investigated in further studies with a large sample size. Fourth, this was a cross-sectional observational study. Longitudinal research is required to establish the causal link between TBA and CAC risk. Fifth, our population was Chinese. Other populations should be used to confirm that the study’s findings are generalizable. In addition, although electrocardiogram-gated (ECG) CT is the standard for CAC evaluation, studies have shown that non-ECG chest CT performs comparably in assessing CAC severity [23, 51]. Lastly, this study did not investigate the potential correlation between aberrant bile acid levels and other cardiovascular conditions such as heart failure or unstable angina.

In conclusion, our study demonstrated that serum TBA was independently associated with CAC, even after comprehensive adjustment for lipid profiles. Elevated TBA levels were significantly correlated with a higher prevalence of CAC. This association exhibited sex-specific patterns and was particularly evident in participants under 50 years of age without diabetes or hypertension. Our findings identify TBA as a factor potentially associated with CAC. Monitoring and modulating TBA levels may therefore have value in assessing CAC or cardiovascular disease risk, possibly complementing conventional risk factors. Further longitudinal studies are warranted to establish the causal relationship between TBA and CAC risk. In addition, experimental research using animal models is warranted to elucidate the precise biological mechanisms through which specific bile acids influence vascular calcification.

Supplementary Material

AMS-22-3-216044-s1.pdf (596.1KB, pdf)

Acknowledgments

Yuxuan Tong and Xiao Chen contributed equally to this work.

Funding Statement

Funding This study was funded by Jiangsu Traditional Chinese Medicine Science and Technology Development Project (ZT202203) and Scientific Research Project of Jiangsu Provincial Association of Chinese Medicine (PDJH2024002).

Ethical approval

Ethics approval was obtained from our institution. The study was conducted in accordance with the Declaration of Helsinki. The need for informed consent was waived by the Ethics Committee of our institution because of the retrospective nature of the study.

Conflict of interest

The authors declare no conflict of interest.

References

  1. Herrmann M, Rodriguez-Blanco G, Balasso M, et al. The role of bile acid metabolism in bone and muscle: from analytics to mechanisms. Crit Rev Clin Lab Sci 2024; 61: 510–28. [DOI] [PubMed] [Google Scholar]
  2. Zhang Z, Lv T, Wang X, et al. Role of the microbiota-gut-heart axis between bile acids and cardiovascular disease. Biomed Pharmacother 2024; 174: 116567. [DOI] [PubMed] [Google Scholar]
  3. Rodríguez-Morató J, Matthan NR. Nutrition and gastrointestinal microbiota, microbial-derived secondary bile acids, and cardiovascular disease. Curr Atheroscler Rep 2020; 22: 47. [DOI] [PubMed] [Google Scholar]
  4. Voiosu A, Wiese S, Voiosu T, Bendtsen F, Møller S. Bile acids and cardiovascular function in cirrhosis. Liver Int 2017; 37: 1420–30. [DOI] [PubMed] [Google Scholar]
  5. Charach L, Charach G, Karniel E, et al. Peripheral vascular disease and carotid artery disease are associated with decreased bile acid excretion. Bioengineering 2023; 10: 935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Jia B, Zou Y, Han X, Bae JW, Jeon CO. Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease. Trends Microbiol 2023; 31: 76–91. [DOI] [PubMed] [Google Scholar]
  7. Li H, Xu G, Shang Q, et al. Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 alpha-hydroxylase. Metabolism 2004; 53: 927–32. [DOI] [PubMed] [Google Scholar]
  8. Gylling H, Hallikainen M, Rajaratnam RA, et al. The metabolism of plant sterols is disturbed in postmenopausal women with coronary artery disease. Metabolism 2009; 58: 401–7. [DOI] [PubMed] [Google Scholar]
  9. Morozova S, Suc-Royer I, Auwerx J. Cholesterol metabolism modulators in future drug therapy for atherosclerosis. Med Sci (Paris) 2005; 21 Spec No: 53–8. [PubMed] [Google Scholar]
  10. Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res 2020; 127: 553–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Qian B, Zhang K, Li Y, Sun K. Update on gut microbiota in cardiovascular diseases. Front Cell Infect Microbiol 2022; 12:1059349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mori H, Torii S, Kutyna M, Sakamoto A, Finn AV, Virmani R. Coronary artery calcification and its progression: what does it mean? JACC Cardiovasc Imaging 2018; 11: 127–42. [DOI] [PubMed] [Google Scholar]
  13. Chen J, Budoff MJ, Reilly MP, et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol 2017; 2: 635–43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol 2014; 63: 1703–14. [DOI] [PubMed] [Google Scholar]
  15. Mehta A, Vasquez N, Ayers CR, et al. Independent association of lipoprotein(a) and coronary artery calcification with atherosclerotic cardiovascular risk. J Am Coll Cardiol 2022; 79: 757–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Zhang W, Jin J, Zhang H, et al. The value of HDL subfractions in predicting cardiovascular outcomes in untreated, diabetic patients with stable coronary artery disease: an age- and gender-matched case-control study. Front Endocrinol (Lausanne) 2022; 13:1041555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Wang J, Huang X, Fu C, Sheng Q, Liu P. Association between triglyceride glucose index, coronary artery calcification and multivessel coronary disease in Chinese patients with acute coronary syndrome. Cardiovasc Diabetol 2022; 21: 187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Wang B, Hua J, Ma L. Triglyceride to high-density lipoprotein ratio can predict coronary artery calcification. Pak J Med Sci 2022; 38: 624–631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Santangelo G, Gherbesi E, Donisi L, et al. Imaging approaches in risk stratification of patients with coronary artery disease: a narrative review. Arch Med Sci 2024; 21: 16–31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Yong Y, Giovannucci J, Pang SN, et al. Coronary artery calcium density and risk of cardiovascular events: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2025; 18: 294–304. [DOI] [PubMed] [Google Scholar]
  21. Suzuki Y, Matsumoto N, Yoda S, Amano Y, Okumura Y. Coronary artery calcium score: current status of clinical application and how to handle the results. J Cardiol 2022; 79: 567–71. [DOI] [PubMed] [Google Scholar]
  22. Christensen JL, Sharma E, Gorvitovskaia A, et al. Impact of slice thickness on the predictive value of lung cancer screening computed tomography in the evaluation of coronary artery calcification. J Am Heart Assoc 2019; 8: e010110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Xie X, Zhao Y, de Bock GH, et al. Validation and prognosis of coronary artery calcium scoring in nontriggered thoracic computed tomography: systematic review and meta-analysis. Circ Cardiovasc Imaging 2023; 6: 514–21. [DOI] [PubMed] [Google Scholar]
  24. Rahoual G, Zeitouni M, Charpentier E, et al. Phenotyping coronary plaque by computed tomography in premature coronary artery disease. Eur Heart J Cardiovasc Imaging 2024; 25: 257–66. [DOI] [PubMed] [Google Scholar]
  25. Rasmussen T, Køber L, Abdulla J, et al. Coronary artery calcification detected in lung cancer screening predicts cardiovascular death. Scand Cardiovasc J 2015; 49: 159–67. [DOI] [PubMed] [Google Scholar]
  26. Chiang JYL, Ferrell JM, Wu Y, Boehme S. Bile acid and cholesterol metabolism in atherosclerotic cardiovascular disease and therapy. Cardiol Plus 2020; 5: 159–70. [PMC free article] [PubMed] [Google Scholar]
  27. Charach G, Karniel E, Novikov I, et al. Reduced bile acid excretion is an independent risk factor for stroke and mortality: a prospective follow-up study. Atherosclerosis 2020; 293: 79–85. [DOI] [PubMed] [Google Scholar]
  28. Li W, Shu S, Cheng L, et al. Fasting serum total bile acid level is associated with coronary artery disease, myocardial infarction, and severity of coronary lesions. Atherosclerosis 2020; 292: 193–200. [DOI] [PubMed] [Google Scholar]
  29. Zhang BC, Chen JH, Xiang CH, Su MY, Zhang XS, Ma YF. Increased serum bile acid level is associated with high-risk coronary artery plaques in an asymptomatic population detected by coronary computed tomography angiography. J Thorac Dis 2019; 11: 5063–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Wang C, Ma Q, Yu X. Bile acid network and vascular calcification-associated diseases: unraveling the intricate connections and therapeutic potential. Clin Interv Aging 2023; 18: 1749–67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Tong Y, Wang Y, Chen X, et al. The triglyceride glucose: high-density lipoprotein cholesterol ratio is associated with coronary artery calcification evaluated via non-gated chest CT. Cardiovasc Diabetol 2024; 23: 376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yamamoto S, Sato I, Fukuhama N, et al. Bile acids aggravate nonalcoholic steatohepatitis and cardiovascular disease in SHRSP5/Dmcr rat model. Exp Mol Pathol 2020; 114: 104437. [DOI] [PubMed] [Google Scholar]
  33. Charach G, Argov O, Geiger K, Charach L, Rogowski O, Grosskopf I. Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome. Therap Adv Gastroenterol 2018; 11: 1756283x17743420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Jovanovich A, Isakova T, Block G, et al. Deoxycholic acid, a metabolite of circulating bile acids, and coronary artery vascular calcification in CKD. Am J Kidney Dis 2018; 71: 27–34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Jovanovich A, Cai X, Frazier R, et al. Deoxycholic acid and coronary artery calcification in the chronic renal insufficiency cohort. J Am Heart Assoc 2022; 11: e022891. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Chong Nguyen C, Duboc D, Rainteau D, et al. Circulating bile acids concentration is predictive of coronary artery disease in human. Sci Rep 2021; 11: 22661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Guan B, Tong J, Hao H, et al. Bile acid coordinates microbiota homeostasis and systemic immunometabolism in cardiometabolic diseases. Acta Pharm Sin B 2022; 12: 2129–49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Jiang Z, Zhuo LB, He Y, et al. The gut microbiota-bile acid axis links the positive association between chronic insomnia and cardiometabolic diseases. Nat Commun 2022; 13: 3002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 2016; 7: 22–39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH, Othman MHD. Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart. Biomolecules 2018; 8: 159. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Li Q, Li Y, Lei C, Tan Y, Yi G. Sphingosine-1-phosphate receptor 3 signaling. Clin Chim Acta 2021; 519: 32–9. [DOI] [PubMed] [Google Scholar]
  42. Bishop-Bailey D, Walsh DT, Warner TD. Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci USA 2004; 101: 3668–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Yu H, Nie R, Shen C. The role of bile acids in regulating glucose and lipid metabolism. Endocr J 2023; 70: 359–74. [DOI] [PubMed] [Google Scholar]
  44. Ding L, Yang L, Wang Z, Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B 2015; 5: 135–44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nat Rev Cardiol 2017; 14: 79–87. [DOI] [PubMed] [Google Scholar]
  46. Lu Q, Chen J, Jiang L, et al. Gut microbiota-derived secondary bile acids, bile acids receptor polymorphisms, and risk of cardiovascular disease in individuals with newly diagnosed type 2 diabetes: a cohort study. Am J Clin Nutr 2024; 119: 324–32. [DOI] [PubMed] [Google Scholar]
  47. Sanchez-Gimenez R, Ahmed-Khodja W, Molina Y, et al. Gut microbiota-derived metabolites and cardiovascular disease risk: a systematic review of prospective cohort studies. Nutrients 2022; 14: 2654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Xu J, Wang N, Yang L, Zhong J, Chen M. Intestinal flora and bile acid interactions impact the progression of diabetic kidney disease. Front Endocrinol 2024; 15: 1441415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Ramírez-Pérez O, Cruz-Ramón V, Chinchilla-López P, Méndez-Sánchez N. The role of the gut microbiota in bile acid metabolism. Ann Hepatol 2017; 16 (Suppl. 1: s3–105.): s15–20. [DOI] [PubMed] [Google Scholar]
  50. Ferraro E, Pozhidaeva L, Pitcher DS, et al. Prolonged ursodeoxycholic acid administration reduces acute ischaemia-induced arrhythmias in adult rat hearts. Sci Rep 2020; 10: 15284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Christensen JL, Sharma E, Gorvitovskaia A, et al. Impact of slice thickness on the predictive value of lung cancer screening computed tomography in the evaluation of coronary artery calcification. J Am Heart Assoc 2019; 8: e010110. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

AMS-22-3-216044-s1.pdf (596.1KB, pdf)

Articles from Archives of Medical Science : AMS are provided here courtesy of Termedia Publishing

RESOURCES